Tafamidis delays neurological progression comparably across Val30Met and non‐Val30Met genotypes in transthyretin familial amyloid polyneuropathy

BACKGROUND AND PURPOSE: To better characterize the effects of tafamidis in non‐Val30Met patients with transthyretin familial amyloid polyneuropathy, this post hoc analysis compared the neurological results from a 12‐month, open‐label study of non‐Val30Met versus Val30Met patients at month 12 from th...

Descripción completa

Detalles Bibliográficos
Autores principales: Gundapaneni, B. K., Sultan, M. B., Keohane, D. J., Schwartz, J. H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5838526/
https://www.ncbi.nlm.nih.gov/pubmed/29115008
http://dx.doi.org/10.1111/ene.13510

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5838526/
https://www.ncbi.nlm.nih.gov/pubmed/29115008
http://dx.doi.org/10.1111/ene.13510

Ejemplares similares